News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|October 21, 2022

Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.

Episodes in this series

EP. 1 Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

EP. 1 Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer

EP. 2 Unmet Needs of Patients with Locally Advanced Metastatic Urothelial Cancer (mUC)

EP. 2 Unmet Needs of Patients with Locally Advanced Metastatic Urothelial Cancer (mUC)

EP. 3 EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape

EP. 3 EV+P Combination Strategy Changing Bladder Cancer Treatment Landscape

EP. 4 SOGUG-AUREA Study Overview

EP. 4 SOGUG-AUREA Study Overview

EP. 5 SOGUG-AUREA Trial Results Impacting Next-Steps for Bladder Cancer Treatment

EP. 5 SOGUG-AUREA Trial Results Impacting Next-Steps for Bladder Cancer Treatment

EP. 6 Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer

EP. 6 Exploring the Role of Disitamab Vedotin in the Treatment of Metastatic Urothelial Cancer

EP. 7 Penpulimab Plus Anlotinib Evaluated for Previously Treated Urothelial Cancers

EP. 7 Penpulimab Plus Anlotinib Evaluated for Previously Treated Urothelial Cancers

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Explore the top dermatology innovations of 2025, from AI-enabled devices to new biologics and emerging treatments for complex skin conditions.

Top 5 Most-Read Dermatology Content of 2025

BySabrina McCrear

December 28th 2025

Highlights From ASH 2025

ICYMI: Highlights From ASH 2025

ByLaura Joszt, MA

December 28th 2025

ICYMI: Highlights From EHA 2025

December 26th 2025

Patient and doctor | Image credit: DragonImages - adobe.stock.com

Sequential BTK and BCL2 Therapy Yields High Initial Real-World Response in CLL

ByKimberly Rath, PharmD

December 26th 2025

The key takeaways from AAD 2025 include expert insights on topical JAK safety, climate-driven skin challenges, tech innovation, and expanding equitable access in dermatology.

ICYMI: Highlights From AAD 2025

BySabrina McCrear

December 25th 2025

Trending on AJMC

Visibility, Not Lesion Burden, Drives Distress in Alopecia Areata

Top 5 Most-Read CLL Articles of 2025

Evidence Suggests Bidirectional Risk Between Ovarian, Colorectal Cancers

Top 5 Most-Read CRC Content in 2025

Top 5 Most-Read "5 Things" Articles of 2025

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.